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Summary Congenital disorders of glycosylation (CDG)
are a family of multisystem inherited disorders caused by
defects in the biosynthesis of N- or O-glycans. Among
the many different subtypes of CDG, the defect of a
mannosyltransferase encoded by the humanALG3 gene
(chromosome 3q27) is known to cause CDG Id. Six
patients with CDG Id have been described in the litera-
ture so far. We further delineate the clinical, biochemi-
cal, neuroradiological and molecular features of CDG
Id by reporting an additional patient bearing a novel
missense mutation in the ALG3 gene. All patients with
CDG Id display a slowly progressive encephalopathy
with microcephaly, severe psychomotor retardation and
epileptic seizures. They also share some typical dysmor-
phic features but they do not present the multisystem
involvement observed in other CDG syndromes or any
biological marker abnormalities. Unusually marked
osteopenia is a feature in some patients and may re-
main undiagnosed until revealed by pathological frac-
tures. Serum transferrin screening for CDG should be
extended to all patients with encephalopathy of unknown
origin, even in the absence of multisystem involvement.
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LLO lipid-linked oligosaccharide
MRI magnetic resonance imaging
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Congenital disorders of glycosylation (CDG) are a
family of heterogeneous multisystem inherited disorders
caused by defects in the biosynthesis of glycoconjugates,
affecting N- or O-glycosylation. N-Glycosylation of pro-
teins starts in the endoplasmic reticulum, where different
enzymes synthesize oligosaccharide chains linked to a
membrane-bound lipid support (dolichol); these chains
are then transferred to proteins. The process continues
in the Golgi apparatus, where protein-bound glycans
undergo remodelling and processing with addition and/
or excision of individual sugars. Defects that alter the
stepwise assembly of the lipid-linked oligosaccharide
(LLO: Glc3Man9GlcNAc2) or its transfer to proteins
within the endoplasmic reticulum are called CDG type I.
In this group of defects, proteins lack entire sugar chains
(glycans); this results in changes in protein folding,
stability and turnover. Defects in the remodelling of
protein-bound glycans in the Golgi are called CDG type
II (Marquardt and Denecke 2003). Both isoelectric
focusing and capillary electrophoresis of serum trans-
ferrin are sensitive screening methods to detect the two
patterns of CDG glycosylation anomaly, pointing to a
defect in one of the two parts of the pathway. Today, at
least 16 different subtypes of N-glycosylation defects
are known (Marquardt and Denecke 2003; Jaeken
and Matthijs 2007; Gru¨newald 2007; Vodopiutz and
Bodamer 2008). Although the clinical diversity of CDG
is remarkable, even within each group, most subtypes
are characterized by a multisystem involvement with
abnormalities in several biological markers.
Mutations in the human ALG3 gene (chromosome
3q27), coding for the first dol-P-Man-dependent man-
nosyltransferase, were recognized as the molecular
defect causing CDG type Id (OMIM #601110) (Ko¨rner
et al 1999) in the first index patient described by Stibler
(Stibler et al 1995). The resulting defect leads to accumu-
lation of the LLO intermediate dol-PP-GlcNAc2Man5.
N-Glycosylation is abnormal owing to the transfer of
truncated LLOs and to the incomplete utilization of
N-glycosylation sites. Six patients with CDG Id
(formerly named CDG type IV) have been reported so
far (Denecke et al 2004, 2005; Ko¨rner et al 1999; Kranz
et al 2007; Schollen et al 2005; Sun et al 2005). Constant
clinical features are severe epilepsy, microcephaly, visual
Fig. 1 Brain MRI of the
patient at age 4 months
(a) and 15 months
(b, c and d). (a) Enlargement
of subarachnoid spaces and
plagiocephalic deformation
of the skull in an axial
T1-weighed image;(b) cortical
atrophy with no abnormal
gyration in an axial
T1-weighed image;(c)
white-matter atrophy
in an axial T2-weighed image;
(d) atrophy of the brainstem
and vermis and thin corpus
callosum in a sagittal
T1-weighed image
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impairment due to optic atrophy, and severely delayed
psychomotor development.
We report a seventh patient with molecularly
confirmed CDG Id in order to further delineate the
clinical, biochemical and radiological features of this
disease.
Case report
Our patient is the third child of healthy non-
consanguineous parents of Swiss and Italian origin.
The family history is unremarkable. Pregnancy and
delivery were uneventful. He was born at term with a
weight of 3790g (>90th centile), a length of 50 cm
(50th–90th centile) and a head circumference of 34 cm
(50th centile). The neonatal period was uneventful.
Epileptic seizures with hypotonia, tonic-clonic move-
ments of the limbs, and eye revulsion started at
4 months and responded initially to benzodiazepines
and phenobarbital. The child presented several dys-
morphic features such as microcephaly, triangular face
with retrognathism, hypertelorism, large low-implanted
ears, widened nasal bridge, adducted thumbs and long,
thin fingers. There was bilateral cryptorchidism. He did
not present inverted nipples, abnormal subcutaneous
fat tissue distribution, heart anomalies or hepatic dys-
function as seen in other patients with CDG syndromes.
Brain MRI performed at 4 months revealed enlarged
subarachnoid spaces and cranial asymmetry (Fig. 1a).
Spectroscopy revealed a discrete lactate elevation
within the white matter in the frontal area. The EEG
showed very frequent discharges (every 30s) from
bi-occipital and bi-temporal focuses, corresponding to
clinical episodes of gaze deviations upwards and
towards the left, followed by rotatory eye movements
and closure. These episodes lasted 6–7s, frequently
accompanied by respiratory pauses. Clinical seizures
and EEG improved under valproate treatment.
At 15 months the patient showed severe growth and
psychomotor retardation. Epilepsy was reasonably
controlled by valproate, with some rare epileptic
seizures triggered by fever. Neurological examination
showed severe axial hypotonia and spastic tetraparesis.
He was unable to sit, to hold his head, and to open his
hands, which were permanently fisted. He could hold
Fig. 2 Phenotypic features of
the patient at age 5 years:
microcephaly, large and
low-set ears, broad and flat
nasal bridge, thin upper lip,
triangular mouth, long and
thin fingers, adducted
thumbs
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objects and bring them to his mouth, but he could not
transfer them from one hand to the other. Visual con-
tact was poor and developmental age was estimated at a
level of 4 months. The clinical course was marked by
repetitive ear and pulmonary infections as well as
gastro-oesophageal reflux. Brain MRI at 15 months of
age (Fig. 1b, c, d) showed diffuse cortico-subcortical
atrophy, progression of white-matter atrophy and mild
atrophy of the vermis. Ophthalmological examination
showed a latent nystagmus triggered by occlusion;
funduscopy revealed hypopigmentation of the retina
and optic atrophy. Abdominal ultrasound was normal,
except for left pyelo-caliceal dilatation without reflux.
No heart anomaly was found on echocardiography.
Metabolic investigations (amino acids, urinary
organic acids, ammonia, lactate, blood pH, very long-
chain fatty acids) were normal. Capillary electropho-
resis analysis of serum transferrin showed a type 1
pattern with increased asialo- and disialotransferrin
and presence of tetrasialotransferrin. CDG type Ia and
Ib were excluded by enzymatic analysis in leukocytes.
Biochemical analysis of dolichol-oligosaccharides and
protein-linked oligosaccharides in fibroblasts revealed
accumulation of truncated Man5-GlcNAc2 oligosaccha-
ride in addition to the mature Glc3Man9GlcNAc2 oligo-
saccharide; this feature is typical of CDG type Id.
Mutation analysis of the ALG3 gene in both the
cDNA and genomic DNA showed two compound
heterozygous mutations, one in exon 1 [c.116C>T,
p.P39L] and the other in exon 4 [c.512G>A, p.R171Q].
Sequencing of exons 1 and 4 of the ALG3 gene in both
parents confirmed segregation (maternal mutation
p.P39L, paternal mutation p.R171Q). The two nucle-
otide changes found in our patient were not present in
100 chromosomes of anonymous unrelated European
controls.
The patient is at present 5 years old, his weight
follows the 3rd centile, his length follows the 25th
centile and his head circumference is far below the 3rd
centile (44 cm). His dysmorphic features are shown in
Fig. 2. He is fed a diversified blended oral diet, with
increasing difficulties due to his gastro-oesophageal














Stibler et al (1995)
Ko¨rner et al (1999)
Sex M F M F F M M
Dysmorphic features
Strabismus ++ ++ + n.k. n.k. + n.k.
Facial dysmorphisms + + + ++ + + +
Inverted nipples j + + + n.k. n.k. j
Subcutaneous fat pads j j j + n.k. n.k. j
Limb abnormalities j j j + + + j
Neurological features
Hypo-/hypertonia ++ + ++ + + + +
Seizures ++ ++ ++ j ++ + +
Visual Impairment ++ + ++ + + + +
Cerebellar/cerebral
hypoplasia
+ + ++ + + + +




Hepatic fibrosis/cirrhosis j j j + n.k. j n.k.
Hypoalbuminemia j ++ ++ + n.k. j n.k.
Coagulopathy j + j + n.k. j n.k.
Protein-losing
enteropathy
j j j n.k. n.k. j n.k.
Hyperinsulinaemic
hypoglycaemia
j j j + n.k. j n.k.




+ j + n.k. n.k. n.k. n.k.
++, very severe; +, symptom present; j, symptom absent; n.k., not known.
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reflux. He attends a special needs school and is pre-
scribed weekly physiotherapy, occupational therapy as
well as assistive devices to improve muscle tone and
comfort. Axial hypotonia remains very severe, with
development of kyphoscoliosis. His movement pattern
is abnormal, with continuous involuntary movements
of the head and the upper limbs. Visual fixation is
disturbed by the continuous head movement and,
although the child seems to recognize familiar faces,
there is no real visual contact. Communication is
limited to undifferentiated vocalization with a better
response to auditory than to visual stimulation. A
pathological fracture of the right humerus recently
occurred during the transfer between two caretakers.
Radiological examination revealed severe osteopenia
without specific bone changes; no shortened long bones
or hypoplastic vertebral bodies and ribs were noted as
reported in other CDG syndromes. Bone density mea-
sured on the lumbar spine showed aZ-score of j3.9 SD.
Several biochemical parameters of multisystem func-
tions were normal at follow-up from 15 months to
5 years, including liver function tests (transaminases,
coagulation tests, plasma albumin), glomerular and
tubular renal function tests (plasma urea and creati-
nine, tubular reabsorption of glucose, electrolytes and
amino acids), muscle enzymes (creatine kinase), nutri-
tional parameters, thyroid hormones, insulin/glucose
ratios, calcium-phosphate metabolism and parathyroid
hormone.
Discussion
On the basis of the clinical features of our patient and
of the published data of the six known patients with
CDG Id, some features of the syndrome seem to be
common (Table 1). Microcephaly due to cerebral
atrophy is mainly present at birth (Kranz et al 2007;
Schollen et al 2005; Sun et al 2005) or develops in the
first months of life as in the present patient (Denecke
et al 2004, 2005; Ko¨rner et al 1999; Stibler et al 1995)
and becomes progressively more evident in comparison
with other growth parameters. An early-onset seizure
disorder, often poorly controlled by antiepileptic medi-
cation, is present in nearly all patients (Denecke et al
2004, 2005; Ko¨rner et al 1999; Kranz et al 2007; Schollen
et al 2005). Psychomotor retardation is usually severe
with very little progress. Only in one of the siblings
described by Kranz and coauthors did psychomotor
development appear to be relatively preserved, with
predominant digestive symptoms (Kranz et al 2007).
There is usually profound axial hypotonia and limb
spasticity. Eye and vision involvement is present in all
patients (Denecke et al 2004, 2005; Ko¨rner et al 1999;
Kranz et al 2007; Stibler et al 1995; Schollen et al 2005;
Sun et al 2005), often characterized by optic atrophy or
strabismus. Club feet and contractures of digits are
frequently seen at birth (Denecke et al 2005; Schollen
et al 2005; Sun et al 2005). Dysmorphic features are
usually mild at birth, but seem to become quite
characteristic with time: the facial appearance and
especially the profile with a broad and flat nasal bridge,
micrognathia, thin upper lip, triangular mouth, down-
slanting palpebral fissures, strabismus, and thickened,
large, low-implanted ears are very similar in our patient
and in the other photographically documented patients
(Denecke et al 2005; Kranz et al 2007; Schollen et al
2005; Sun et al 2005); long and thin fingers seem to be
typical (Kranz et al 2007; Sun et al 2005). Gastrointes-
tinal symptoms such as recurrent vomiting (Denecke
et al 2004, 2005), diarrhoea and food intolerance (Kranz
et al 2007) are described in some cases and our patient
presented gastro-oesophageal reflux. Metabolic abnor-
malities were reported in only one patient (Sun et al
2005), who presented with hyperinsulinaemic hypogly-
caemia. Hypoglycaemia may have occurred in other
patients but was not documented; in our patient no
hypoglycaemia was found and fasting insulin/glucose
ratio was normal. Some aspects of the disease such as
failure to thrive and orthopaedic complications may be
considered secondary effects of the neurological handi-
cap rather than primary phenotypic features. Osteo-
penia may be linked to pathological muscular tone and
immobilization. However, pathological fractures have
been described in another CDG Id patient (Kranz et al
2007) at an early age (5 years in our patient): this
suggests that osteopenia may result from a primary
disturbance of bone mineralization (Coman et al 2008).
In contrast to other CDG types, CDG Id presents
less multi-organic involvement; the phenotype is mainly
dysmorphic and neurological. The prognosis and life-
span of CDG Id patients is difficult to assess because of
the small number of known cases and the lack of
detailed long-term follow-up descriptions. The clinical
course is slowly progressive without episodes of decom-
pensation and/or acute deterioration and without
multisystem involvement as in other inherited meta-
bolic disorders. Infections do not seem to trigger disease
progression. Prognostic considerations may be very simi-
lar to those in other syndromic, non-metabolic severe
encephalopathies, with respiratory and/or digestive com-
plications expected as in other severely hypotonic
patients. More insights on organ-specific pathophysio-
logical mechanisms of CDG Id are probably needed
to distinguish between primary and secondary signs of
the disease.
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The patient described here is compound heterozy-
gote for two missense mutations in the ALG3 gene
causing CDG Id. The first mutation, p.P39L, has not
been described so far. The second mutation, p.R171Q,
was found at the homozygous state in the severe case
of Sun and coauthors (Sun et al 2005); this patient
manifested prenatal clinical signs and died in the
neonatal period. Multiple sequence alignment of the
ALG3 protein in different species showed that both
proline 39 and arginine 171 are conserved in human,
dog, mouse, and Drosophila (data not shown). Con-
servation through species and absence in controls
strongly support the pathogenic role of p.P39L. The
two missense mutations found in our patient lead to
altered N-glycosylation, as shown by the typical accumu-
lation of truncated LLOs in our patient_s fibroblasts.
However, the presence of mature Glc3Man9GlcNAc2
oligosaccharides reflects a residual mannosyltransferase
activity. This residual activity might be important for
future development of therapy for CDG Id. Indeed,
Denecke and coauthors pointed at the possible role of
maternal or placental factors responsible for a partially
compensated N-glycosylation in CDG Id during preg-
nancy (Denecke et al 2005). Whether these factors
compensate N-glycosylation by enhancing the residual
enzymatic activity or through other mechanisms
(chaperones?) remains to be clarified.
ALG3 gene analysis allows prenatal diagnosis in
families with CDG Id index cases. The analysis of LLO
in chorion cells could also be a helpful tool as shown by
Denecke and coauthors (Denecke et al 2005). Serum
transferrin profile is a simple screening test for CDG
syndromes. Although multisystem involvement is usu-
ally considered a prerequisite for CDG screening,
recent reports mention the existence of organ-specific
CDG syndromes (Jaeken and Matthijs 2007). The pre-
sent report underlines that epileptic encephalopathy can
be the only phenotypic manifestation of a CDG
syndrome and suggests that transferrin screening should
be extended to all patients presenting an encephalopa-
thy of unknown origin.
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